FDAsafety guidance83% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to nontuberculous mycobacterial lung disease patients.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Pulmonology · Nontuberculous Mycobacterial Lung Disease
- Sub-indication
- General
Related signal: Inhaled 3% hypertonic saline shows promise for antibiotic-naïve NTM lung disease